CONRAD, a leading organization in reproductive health research, is developing new ways to protect women from acquiring infections, especially HIV/AIDS. CONRAD links basic and clinical research and brings investigators in the laboratory and the field together, whether they are employed by government agencies, nongovernmental organizations, foundations, or the private sector. In the development of microbicides, CONRAD’s primary goals are to develop safe, effective, acceptable, and affordable products.
CONRAD scientists have been instrumental in advancing several microbicide candidates including first generation candidates PRO2000, BufferGel, Savvy, and cellulose sulfate, and second generation candidates tenofovir (TFV) and UC781. First generation microbicides focused on killing or inactivating pathogens, strengthening the vagina’s natural defenses, or blocking the virus from entering the vaginal mucosa. Unfortunately, the first generation microbicides did not prove efficacious in clinical trials. Today, reverse transcriptase inhibitors (RTIs) and other antiretrovirals are being formulated as microbicides for the prevention of HIV. CONRAD's current efforts are focused on TFV, the active ingredient in the first microbicide gel to be shown to prevent HIV in women.
To learn more about CONRAD’s preclinical microbicide activities, click here.
To learn more about CONRAD’s clinical microbicide activities, click here.
Multipurpose Prevention Technologies: The ability to use a single product to prevent unplanned pregnancy and sexually transmitted infections (STIs), including HIV, would provide women with a simplified, more acceptable, and potentially less expensive choice for protection. To this end, CONRAD is developing contraceptive/anti-HIV technologies. Learn more about multipurpose prevention technologies in development here.